Type of opioid pharmacotherapy treatment code N

Exported from METEOR

(AIHW's Metadata Online Registry)

© Australian Institute of Health and Welfare 2024

This product, excluding the AIHW logo, Commonwealth Coat of Arms and any material owned by a third party or protected by a trademark, has been released under a Creative Commons BY 4.0 (CC BY 4.0) licence. Excluded material owned by third parties may include, for example, design and layout, images obtained under licence from third parties and signatures. We have made all reasonable efforts to identify and label material owned by third parties.

You may distribute, remix and build on this website’s material but must attribute the AIHW as the copyright holder, in line with our attribution policy. The full terms and conditions of this licence are available at https://creativecommons.org/licenses/by/4.0/.

Enquiries relating to copyright should be addressed to info@aihw.gov.au.

Enquiries or comments on the METEOR metadata or download should be directed to the METEOR team at meteor@aihw.gov.au.

# Type of opioid pharmacotherapy treatment code N

|  |
| --- |
| Identifying and definitional attributes |
| Metadata item type: | Value Domain |
| METEOR identifier: | 696818 |
| Registration status: | [Health](https://meteor.aihw.gov.au/RegistrationAuthority/12), Qualified 06/07/2023 |
| Definition: | A code set representing a type of drug-based opioid treatment program. |

|  |
| --- |
| Representational attributes |
| Representation class: | Code |
| Data type: | Number |
| Format: | N |
| Maximum character length: | 1 |
|   | **Value** | **Meaning** |
| Permissible values: | 1 | Methadone |
|   | 2 | Buprenorphine-naloxone |
|   | 3 | Buprenorphine long-acting injection |
|   | 4 | Buprenorphine |
|   | 5  | Naltrexone  |

|  |
| --- |
| Collection and usage attributes |
| Guide for use: | CODE 1   MethadoneIncludes treatment programs whereby the administered opioid substitute is methadone.CODE 2   Buprenorphine-naloxoneIncludes treatment programs whereby the administered opioid substitute is buprenorphine-naloxone such as Suboxone.CODE 3   Buprenorphine long-acting injectionIncludes treatment programs whereby the administered opioid substitute is buprenorphine long-acting injection such as Buvidal, Sublocade.CODE 4   Buprenorphine Includes treatment programs whereby the administered opioid substitute is buprenorphine such as Subutex, Probuphine.CODE 5   Naltrexone Includes treatment programs whereby the administered opioid substitute is naltrexone. |
| Comments: | Opiate substitution programs use a long-acting synthetic opiate medication, usually methadone or levo-alpha acetyl methadol, administered orally for a sustained period at a dosage sufficient to prevent opiate withdrawal, block the effects of illicit opiate use and decrease opiate craving. |

|  |
| --- |
| Source and reference attributes |
| Submitting organisation: | Australian Institute of Health and Welfare |
| Reference documents: | Australian Institute of Health and Welfare (2022) [National Opioid Pharmacotherapy Statistics Annual Data collection](https://www.aihw.gov.au/reports/alcohol-other-drug-treatment-services/national-opioid-pharmacotherapy-statistics), AIHW, Australian Government, accessed 21 September 2022. |

|  |
| --- |
| Relational attributes  |
| Related metadata references: | Supersedes [Type of opioid pharmacotherapy treatment code N](https://meteor.aihw.gov.au/content/404755)       [Health](https://meteor.aihw.gov.au/RegistrationAuthority/12), Standard 25/08/2011 |
| Data elements implementing this value domain: | [Person—type of opioid pharmacotherapy treatment, code N](https://meteor.aihw.gov.au/content/696815)       [Health](https://meteor.aihw.gov.au/RegistrationAuthority/12), Qualified 06/07/2023 |